sustain 6 trial semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category | Diabetes Therapy Semaglutide: The Drug of Today

Liver enzymes, such as serum aminotransferases, commonly elevate in fatty liver disease, indicating stress or damage

Gut microbiome modulators represent another exciting development

On average, participants lost around 15% of their body weight over the course of the trial

Injectable formulations like Ozempic, Trulicity, and Mounjaro are widely prescribed, with user-friendly pen devices enhancing patient compliance

Amino acid imbalance is an independent factor for mortality in patients with liver cirrhosis

The mean (SD) number of supplements used per patient was 1.3 (1.5), with a median of 1 and a range of 0 to 17